What happened Shares of gene-editing specialist Editas Medicine (NASDAQ: EDIT) are falling sharply on Friday and were down by 16.7% as of 2:02 p.m. EDT. The company did not report any news, but these losses are probably a result of bearish commentary from a Wall Street analyst. So what Goldman Sachs analyst Madhu Kumar initiated coverage of Editas Medicine with a sell rating Friday. The analyst also gave the stock a price target of $20. Editas Medicine's share price as of the closing of business day yesterday was $40.98. And even after today's sell-off, Editas Medicine stock is priced at $34.21 (as of this writing), which means there remains a sizable downside for the biotech if we go by Kumar's price target. Image source: Getty Images. One reason behind the analyst's bearish sentiment is Editas Medicine's EDIT-101, a potential treatment for a rare eye disease called Leber congenital amaurosis. Initial results do not indicate that EDIT-101 could meaningfully improve patients' vision, according to Kumar. Overall, the analyst thinks the biotech's risk-reward profile is not attractive. Now what Should investors avoid Editas Medicine following this vote of no-confidence from Kumar? There is no question that the healthcare company has a long, arduous, and volatile road ahead. After all, it will be years before Editas Medicine can even hope to launch a product on the market, and a lot can happen in the meantime. On the flip side, the company could go on to develop treatments for rare and otherwise difficult to treat illnesses thanks to its gene-editing technology. The success of its programs could translate into market-beating returns in the long run. In other words, Editas Medicine is a high-risk, high-reward play, but that's nothing new. In my view, investors with above-average risk tolerance -- and who are willing to be patient -- should still consider purchasing shares of this biotech stock. 10 stocks we like better than Editas MedicineWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Editas Medicine wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of February 24, 2021 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Editas Medicine. The Motley Fool has a disclosure policy.Source